Thursday, June 11, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Metastatic Lung Cancer


Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts

Wendi S Lee, MSN, RN, NP-C
Department of Thoracic/Head and Neck
Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Suresh S Ramalingam, MD
Professor of Hematology and Medical Oncology
Roberto C Goizueta Chair for Cancer Research
Director, Division of Medical Oncology
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Frequency, significance and identification of actionable tumor mutations in non-small cell lung cancer (NSCLC)
  • Optimal first-line therapy for lung cancer with an activating EGFR mutation (FLAURA study): Role of osimertinib, including for patients with brain metastases
  • Recent advances shaping the treatment of lung cancer with other targetable abnormalities (ALK, ROS1, BRAF, NTRK, RET, MET exon 14)
  • Sequencing immune checkpoint inhibitors for patients with metastatic NSCLC (mNSCLC) and targetable tumor mutations
  • Counseling patients who are about to begin targeted therapy for NSCLC regarding unique tolerability considerations
  • Factors affecting the selection of anti-PD-1 antibody monotherapy versus chemotherapy/immune checkpoint inhibitor with or without bevacizumab for mNSCLC
  • Emerging data with front-line anti-PD-1/PD-L1 and anti-CTLA-4 combination therapy for mNSCLC (CheckMate 227, POSEIDON studies)
  • Platinum/etoposide combined with an immune checkpoint inhibitor as first-line therapy for extensive-stage small cell lung cancer (SCLC): Recent FDA approvals of durvalumab on the basis of the Phase III CASPIAN study and atezolizumab on the basis of the Phase III IMpower133 trial
  • Prevention, recognition and management of immune-mediated side effects in patients receiving anti-PD-1/PD-L1 therapies

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Recognize the incidence of genetic abnormalities commonly identified in patients with non-small cell lung cancer (NSCLC), and counsel patients regarding how these alterations may predict potential response (or lack thereof) to targeted therapy.
  • Review recent therapeutic advances related to the long-term clinical care of patients with NSCLC and an EGFR tumor mutation, and discern how this information should be applied in practice.
  • Assess other oncogenic signaling pathways (eg, ALK, ROS1, MET, RET) mediating the growth of tumors in unique subsets of patients, and recall published data with commercially available and experimental agents exploiting these targets.
  • Develop an understanding of the biologic basis for the investigation of immune checkpoint inhibitors for advanced NSCLC and small cell lung cancer (SCLC).
  • Appreciate available clinical trial data with and the current role of anti-PD-1/PD-L1 antibodies alone or in combination with chemotherapy and/or anti-angiogenic agents for patients with metastatic NSCLC.
  • Evaluate recently published clinical trial data with the use of an anti-PD-1/PD-L1 antibody in combination with etoposide/platinum chemotherapy as first-line treatment for extensive-stage SCLC, and identify patients appropriate for this novel approach.
  • Educate patients about the side effects associated with therapies commonly used in the management of lung cancer, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NSCLC and SCLC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Goodwin has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms LeeConsulting Agreement: Pfizer Inc. Dr RamalingamConsulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, a GSK Company. Dr RielyAdvisory Committee and Consulting Agreements: Daiichi Sankyo Inc, Takeda Oncology; Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.